Results 171 to 180 of about 7,389 (213)
Evaluation of Spectral Domain OCT Changes Following Anti-VEGF Therapy in Diabetic Macular Edema.
J Pharm Bioallied SciMandloi G +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pseudophakic Cystoid Macular Oedema
2021Pseudophakic cystoid macular oedema (PCMO), Irvine-Gass syndrome, is defined as oedema newly formed after cataract surgery, which is associated with symptomatic vision loss 6/12 or worse. The incidence of angiographic PCMO 1–2 months postoperatively has been reported as high as 20–30% and OCT PCMO 4–41%.
exaly +2 more sources
Cystoid macular oedema following cataract surgery: A review
Clinical and Experimental Ophthalmology, 2019AbstractPseudophakic cystoid macular oedema (PCMO) remains a significant cause of compromised postoperative vision in contemporary cataract surgery. Well‐established risk factors include intraoperative complications such as posterior capsule rupture and preoperative factors including: diabetes mellitus, uveitis, retinal vein occlusion, epiretinal ...
Jina V Han +2 more
exaly +3 more sources
Nepafenac for cystoid macular oedema secondary to paclitaxel
Archivos de la Sociedad Española de Oftalmología (English Edition), 2021Paclitaxel is used to treat a wide range of malignant tumours. This type of drug is known to cause ocular adverse effects, with cystoid macular oedema being a known, but rare complication, of this therapy. Although most cases resolve after discontinuation of the drug, several authors have attempted various treatments to accelerate resolution, or when ...
H E, Tapia Quijada +4 more
openaire +2 more sources
Fundus autofluorescence in the diagnosis of cystoid macular oedema
British Journal of Ophthalmology, 2008To determine the sensitivity and specificity of the non-invasive imaging technique, fundus autofluorescence (AF), in the diagnosis of cystoid macular oedema (CMO), using fluorescein angiography as the reference standard.Retrospective, consecutive, observational case series.Ninety-six consecutive patients with CMO suspected clinically were selected from
McBain, V.A., Forrester, J.V., Lois, N.
openaire +3 more sources
Fingolimod‐associated cystoid macular oedema
Acta Ophthalmologica, 2014AbstractFingolimod‐associated cystoid macular oedema has been reported in treatment of MS and following renal transplantation. This seems to be dose‐dependent with an incidence of approximately 0.5% with 0.5mg oral dose. Although most patients develop macular oedema between 3 to 4 months after initiation, we reported an incidence as early as 5 days ...
L LIU, F CUTHBERTSON
openaire +1 more source
Retinal Angiomatosis and Cystoid Macular Oedema in Cogan's Syndrome
Optometry and Vision Science, 2011ABSTRACT Purpose. To describe clinical features and visual and therapeutic outcomes in a patient affected by Cogan's syndrome with retinal angiomatosis and cystoid macular edema (CMO). Case report.
SEMERARO, Francesco +4 more
openaire +3 more sources
Ibrutinib induced cystoid Macular oedema
Journal of Clinical and Medical Images, Case Reports, 2023Ibrutinib is a small-molecule drug approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. Although it has been connected to ocular side effects, few clinical cases explain cystoid macular oedema associated with long-term Ibrutinib treatment.
openaire +1 more source